Loading organizations...
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2022 | Cleerly | $220.0M Series C | Fidelity Management & Research Company, T. Rowe Price Associates | Canaan Partners, Founders Fund, Index Ventures, Morgenthaler Ventures, Presight Capital, Vensana Capital, Avid Larizadeh, Mato Peric, Peter Thiel, Breyer Capital, Cigna Ventures, DigiTx Partners, LRVHealth, Mirae Asset Capital, Novartis, Piper Jaffray, Sands Capital |
| Nov 1, 2021 | Antios Therapeutics | $75.0M Series B | EPIQ Capital Group, Craig Gordon | Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Altium Capital, Amzak Health, Avego Bioscience Capital, CAM Capital, Delos Capital, Granite Point Capital, GRA Venture Fund, LifeSci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital, Soleus Capital |